Information  X 
Enter a valid email address

Ondine Boipharma Cor (OBP)

  Print   

Tuesday 29 June, 2010

Ondine Boipharma Cor

Ondine To Form Chronic Sinusitis Treatment Subs...



FOR:  ONDINE BIOPHARMA CORPORATION

TSX, AIM SYMBOL:  OBP

June 29, 2010

Ondine To Form Chronic Sinusitis Treatment Subsidiary

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 29, 2010) - Ondine Biopharma Corporation (the
"Company" or "Ondine") (TSX:OBP)(AIM:OBP) a medical technology company developing photodisinfection
based products, today announced its intention to establish a wholly owned subsidiary, "Sinuwave
Technologies Corporation", dedicated to the development and commercialization of photodisinfection
based products that address the chronic sinusitis market. The subsidiary will license all relevant
Ondine intellectual property and know-how for this application, including technology internally
developed over the past ten years and technology obtained in Ondine's December 2009 acquisition of
Advanced Photodynamic Technologies Inc. ("APT"). Sinuwave Technologies will leverage the product
development, clinical and regulatory experiences of both the Ondine and APT teams.

"We believe the powerful antimicrobial and anti-inflammatory benefits of Ondine's photodisinfection
technology have the potential to provide substantial relief to persons who suffer from chronic
sinusitis," says Carolyn Cross, Chairman & CEO of Ondine Biopharma Corporation. "Over 43 million
people in North America suffer from sinusitis. There are over 450,000 patients for whom sinus
surgeries and antibiotics have been unsuccessful. We believe that we can apply our expertise as global
leaders in photodisinfection to address this large unmet patient need."

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial,
fungal and viral infections. The Company is focused on developing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy
without encouraging the formation and spread of antibiotic resistance. The Company is based in
Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell,
Washington, USA.

For additional information, please visit www.ondinebiopharma.com and www.sinuwave.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may",
"expect" and other similar expressions, are forward-looking statements that involve a number of risks
and uncertainties. Factors that could cause actual results to differ materially from those projected
in the Company's forward-looking statements include the following: market acceptance of our
technologies and products; our ability to obtain financing; our financial and technical resources
relative to those of our competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our intellectual property rights and
protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the
timing of commercial product launches; the ability to achieve key technical milestones in key products
and other risk factors identified from time to time in the Company's public filings.

FOR FURTHER INFORMATION PLEASE CONTACT:

Ondine Biopharma Corporation
Carolyn Cross
Chairman and Chief Executive Officer
(604) 669-0555
[email protected]
www.ondinebiopharma.com

OR

Canaccord Genuity Limited, Nominated Adviser
Ryan Gaffney
Nominated Adviser
+4420 7050 6500

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of
this release.

Ondine Biopharma Corporation								

						                                                                  

a d v e r t i s e m e n t